<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-3 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-3</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-3</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>study_title</strong></td>
                        <td>str</td>
                        <td>Full title of the paper or trial report (e.g., 'Neoadjuvant Pembrolizumab in Resectable Stage III Melanoma').</td>
                    </tr>
                    <tr>
                        <td><strong>trial_name_or_id</strong></td>
                        <td>str</td>
                        <td>Named trial or registration ID (e.g., SWOG S1801, OpACIN, OpACIN-neo, PRADO, NCT number).</td>
                    </tr>
                    <tr>
                        <td><strong>citation</strong></td>
                        <td>str</td>
                        <td>First author and journal reference in short form (e.g., 'Amaria et al., NEJM 2022').</td>
                    </tr>
                    <tr>
                        <td><strong>year</strong></td>
                        <td>int</td>
                        <td>Publication year.</td>
                    </tr>
                    <tr>
                        <td><strong>study_design</strong></td>
                        <td>str</td>
                        <td>Design and phase (e.g., 'Phase II randomized', 'Phase III RCT', 'single-arm translational').</td>
                    </tr>
                    <tr>
                        <td><strong>has_direct_comparison</strong></td>
                        <td>bool</td>
                        <td>Does the study directly compare neoadjuvant-plus-adjuvant versus adjuvant-only immunotherapy in melanoma? (true/false)</td>
                    </tr>
                    <tr>
                        <td><strong>arms_description</strong></td>
                        <td>str</td>
                        <td>Concise description of study arms (e.g., 'neoadjuvant pembrolizumab x3 then surgery + adjuvant pembro vs surgery then adjuvant pembro').</td>
                    </tr>
                    <tr>
                        <td><strong>patient_population</strong></td>
                        <td>str</td>
                        <td>Population description (e.g., 'resectable stage IIIB–IIID/IV melanoma'; mucosal/acral included/excluded).</td>
                    </tr>
                    <tr>
                        <td><strong>stage_criteria</strong></td>
                        <td>str</td>
                        <td>Disease stage and resectability criteria used for enrollment.</td>
                    </tr>
                    <tr>
                        <td><strong>sample_size_total</strong></td>
                        <td>int</td>
                        <td>Total number of patients enrolled.</td>
                    </tr>
                    <tr>
                        <td><strong>sample_size_per_arm</strong></td>
                        <td>str</td>
                        <td>Number of patients per arm (e.g., 'neo+adj n=154; adj-only n=159').</td>
                    </tr>
                    <tr>
                        <td><strong>intervention_neoadjuvant</strong></td>
                        <td>str</td>
                        <td>Neoadjuvant regimen, drugs, doses (e.g., 'pembrolizumab 200 mg q3w x3').</td>
                    </tr>
                    <tr>
                        <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                        <td>str</td>
                        <td>Number of cycles and timing relative to surgery (e.g., '2 cycles over 6 weeks; surgery at week 6').</td>
                    </tr>
                    <tr>
                        <td><strong>intervention_adjuvant</strong></td>
                        <td>str</td>
                        <td>Postoperative adjuvant regimen in the neoadjuvant arm (e.g., 'pembro for up to 1 year').</td>
                    </tr>
                    <tr>
                        <td><strong>comparator_adjuvant_only</strong></td>
                        <td>str</td>
                        <td>Adjuvant-only regimen in the control arm (e.g., 'adjuvant pembro 1 year').</td>
                    </tr>
                    <tr>
                        <td><strong>time_to_surgery</strong></td>
                        <td>str</td>
                        <td>Timing metrics around surgery (median time from start to surgery; any protocol-defined windows).</td>
                    </tr>
                    <tr>
                        <td><strong>surgery_feasibility_missed_surgery</strong></td>
                        <td>str</td>
                        <td>Rates of on-time surgery, delays, downstaging, missed resections, or conversion to unresectable.</td>
                    </tr>
                    <tr>
                        <td><strong>pathologic_response_definition</strong></td>
                        <td>str</td>
                        <td>Definitions used (e.g., pCR=0% viable tumor; MPR=≤10% viable).</td>
                    </tr>
                    <tr>
                        <td><strong>pcr_rate_neoadjuvant</strong></td>
                        <td>str</td>
                        <td>Pathologic complete response rate in neoadjuvant-treated surgical specimens (include n/N and %).</td>
                    </tr>
                    <tr>
                        <td><strong>mpr_rate_neoadjuvant</strong></td>
                        <td>str</td>
                        <td>Major pathologic response rate (include definition and %).</td>
                    </tr>
                    <tr>
                        <td><strong>association_path_response_with_survival</strong></td>
                        <td>str</td>
                        <td>Association between pathologic response (pCR/MPR) and EFS/RFS/OS (e.g., HRs, Kaplan–Meier separation).</td>
                    </tr>
                    <tr>
                        <td><strong>clinical_endpoints_reported</strong></td>
                        <td>str</td>
                        <td>Which endpoints were reported (EFS, RFS, OS, DMFS), including timepoints.</td>
                    </tr>
                    <tr>
                        <td><strong>event_free_survival</strong></td>
                        <td>str</td>
                        <td>EFS results comparing arms (HR with CI/p-value; absolute % at specific timepoints).</td>
                    </tr>
                    <tr>
                        <td><strong>recurrence_free_survival</strong></td>
                        <td>str</td>
                        <td>RFS results comparing arms (HR with CI/p-value; absolute % at timepoints).</td>
                    </tr>
                    <tr>
                        <td><strong>overall_survival</strong></td>
                        <td>str</td>
                        <td>OS results comparing arms (HR with CI/p-value; absolute % at timepoints).</td>
                    </tr>
                    <tr>
                        <td><strong>distant_metastasis_free_survival</strong></td>
                        <td>str</td>
                        <td>DMFS results comparing arms (HR with CI/p-value; absolute % at timepoints).</td>
                    </tr>
                    <tr>
                        <td><strong>hazard_ratios_and_CIs</strong></td>
                        <td>str</td>
                        <td>All reported HRs with 95% CIs for primary/secondary endpoints.</td>
                    </tr>
                    <tr>
                        <td><strong>absolute_benefit_timepoints</strong></td>
                        <td>str</td>
                        <td>Absolute differences at prespecified timepoints (e.g., 2-yr EFS +12%).</td>
                    </tr>
                    <tr>
                        <td><strong>follow_up_duration_median</strong></td>
                        <td>str</td>
                        <td>Median follow-up duration and IQR/range if available.</td>
                    </tr>
                    <tr>
                        <td><strong>immune_correlates_summary</strong></td>
                        <td>str</td>
                        <td>High-level summary of mechanistic/immune findings relevant to neoadjuvant benefit.</td>
                    </tr>
                    <tr>
                        <td><strong>peripheral_immune_findings</strong></td>
                        <td>str</td>
                        <td>Peripheral blood immune changes (e.g., expansion of tumor-reactive TCR clones, cytokines).</td>
                    </tr>
                    <tr>
                        <td><strong>intratumoral_immune_findings</strong></td>
                        <td>str</td>
                        <td>Tumor microenvironment changes (e.g., increased CD8+ TILs, IFN-γ gene signatures, PD-L1 upregulation).</td>
                    </tr>
                    <tr>
                        <td><strong>tcr_repertoire_changes</strong></td>
                        <td>str</td>
                        <td>Evidence for TCR clonality/diversity changes and trafficking between tumor and blood.</td>
                    </tr>
                    <tr>
                        <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                        <td>str</td>
                        <td>Evidence for antigen/epitope spreading after neoadjuvant therapy.</td>
                    </tr>
                    <tr>
                        <td><strong>biomarker_predictors</strong></td>
                        <td>str</td>
                        <td>Baseline or on-treatment biomarkers associated with benefit (e.g., PD-L1, TMB, gene signatures).</td>
                    </tr>
                    <tr>
                        <td><strong>mechanism_claims_by_authors</strong></td>
                        <td>str</td>
                        <td>Authors' stated mechanistic rationale for why neoadjuvant improves outcomes (concise quotes or summaries).</td>
                    </tr>
                    <tr>
                        <td><strong>safety_grade3plus_irAE</strong></td>
                        <td>str</td>
                        <td>Rates of grade ≥3 immune-related AEs per arm; include specific toxicities if reported.</td>
                    </tr>
                    <tr>
                        <td><strong>treatment_related_deaths</strong></td>
                        <td>str</td>
                        <td>Any treatment-related mortality and context.</td>
                    </tr>
                    <tr>
                        <td><strong>adjuvant_discontinuation_rate</strong></td>
                        <td>str</td>
                        <td>Rates of adjuvant discontinuation due to AEs in each arm.</td>
                    </tr>
                    <tr>
                        <td><strong>surgical_complications_or_delay</strong></td>
                        <td>str</td>
                        <td>Surgical morbidity, wound complications, and delay rates attributable to neoadjuvant therapy.</td>
                    </tr>
                    <tr>
                        <td><strong>subgroup_analyses</strong></td>
                        <td>str</td>
                        <td>Subgroup results (e.g., by stage, PD-L1 status, BRAF status) and interaction p-values if reported.</td>
                    </tr>
                    <tr>
                        <td><strong>recurrence_patterns</strong></td>
                        <td>str</td>
                        <td>Patterns of failure (local/regional vs distant) by arm.</td>
                    </tr>
                    <tr>
                        <td><strong>resistance_mechanisms</strong></td>
                        <td>str</td>
                        <td>Proposed or observed mechanisms of resistance in the neoadjuvant context.</td>
                    </tr>
                    <tr>
                        <td><strong>counterevidence_or_null_results</strong></td>
                        <td>str</td>
                        <td>Findings that challenge the benefit of neoadjuvant therapy or show no advantage vs adjuvant-only.</td>
                    </tr>
                    <tr>
                        <td><strong>limitations_and_biases</strong></td>
                        <td>str</td>
                        <td>Key limitations (sample size, early stopping, imbalance, follow-up duration) and potential biases.</td>
                    </tr>
                    <tr>
                        <td><strong>funding_and_conflicts</strong></td>
                        <td>str</td>
                        <td>Funding sources and conflicts of interest.</td>
                    </tr>
                    <tr>
                        <td><strong>trial_registration</strong></td>
                        <td>str</td>
                        <td>Clinical trial registration (e.g., NCT number) and registry link if available.</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>